Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson DARZALEX (daratumumab) — U.S. sales by Year
DARZALEX (daratumumab) — U.S. sales ($M) ($M)
Johnson & Johnson DARZALEX (daratumumab) — U.S. sales: $8,266M in FY2025, up 25.5% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-11) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DARZALEX (daratumumab) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 8,266 | +25.5% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 6,588 | +24.8% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 5,277 | +25.3% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 4,210 | +32.8% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 3,169 | +42.0% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 2,232 | +42.4% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 1,567 | +30.3% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 1,203 | +36.1% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 884 | +87.7% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 471 | – | Form 10-K (filed 2019-02-20) ↗ |
Breakdown
What makes up DARZALEX (daratumumab) — U.S. sales
Cite this data
StockData. (2026). Johnson & Johnson DARZALEX (daratumumab) — U.S. sales ($M), annual FY2016–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-darzalex-us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.